Cardiol Therapeutics (TSE:CRDL) Sets New 1-Year Low – Time to Sell?

Cardiol Therapeutics Inc. (TSE:CRDL) shares reached a new 52-week low during trading on Friday . The company traded as low as C$1.69 and last traded at C$1.70, with a volume of 80251 shares changing hands. The stock had previously closed at C$1.75.

Cardiol Therapeutics Trading Down 1.7 %

The firm has a market cap of C$142.72 million, a PE ratio of -3.38 and a beta of 0.70. The company has a current ratio of 2.49, a quick ratio of 6.84 and a debt-to-equity ratio of 1.59. The business has a fifty day moving average price of C$1.91 and a 200 day moving average price of C$2.39.

Insider Buying and Selling

In other news, Senior Officer Guillermo Torre purchased 17,240 shares of the company’s stock in a transaction that occurred on Thursday, December 26th. The shares were purchased at an average price of C$1.81 per share, for a total transaction of C$31,277.77. Also, Senior Officer Andrew Warwick Hamer acquired 18,900 shares of the firm’s stock in a transaction on Thursday, December 19th. The shares were bought at an average cost of C$1.88 per share, with a total value of C$35,606.69. Insiders have bought 86,140 shares of company stock worth $161,456 in the last quarter. 4.57% of the stock is owned by insiders.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.